Objectives

After participating in this educational activity, attendees should be able to:
1| Describe the mechanism of action of the SGLT2i.
2| Consider clinical trial data showing CV and renal benefits of the SGLT2i.
3| Implement SGLT2i properly into the clinical care of patients.

 

Presenter(s): 

Silvio Inzucchi, MD
Professor of Medicine, Yale University School of Medicine
Clinical Chief, Section of Endocrinology
Medical Director, Yale Diabetes Center
Program Director, Endocrinology & Metabolism Fellowship
 
NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Silvio Inzucchi, MD Speaker

Novo Nordisk, Consultant

Astra Zeneca, Consultant

Boehringer Ingelheim, Consultant

Corcept, Consultant

Madrigal, Consultant

AnaCardo, Consultant

No

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

 

Session date: 
10/06/2026 - 12:00pm to 1:00pm EDT
Location: 
Webinar
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category 1 CME credit
    Baystate Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PA’s should only claim credit commensurate with the extent of their participation.
  • 1.00 ACPE Contact Hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 IPCE Credit Hour(s)
Please login or register to take this course.
Faculty List: 
Speaker(s)

Silvio Inzucchi

has a financial relationship (Financial Support) with Novo Nordisk;.
has a financial relationship (Financial Support) with Astra Zeneca;.
has a financial relationship (Financial Support) with Boehringer Ingelheim;.
has a financial relationship (Financial Support) with Corcept;.
has a financial relationship (Financial Support) with Madrigal;.
has a financial relationship (Financial Support) with AnaCardio;.